Abstract:IL‐33 isoforms generated through allergen‐driven proteolysis, signal through NF‐κB at varying intensities. The magnitude of IL‐33 signalling is determined by asthma‐associated structural variation in IL33 receptor. Variation in the IL‐33 receptor extracellular domain alters accessibility of the IL‐33 ligand binding site. Introduction The interleukin‐33/interleukin‐1 receptor‐like‐1 (IL‐33/IL1RL1) signalling pathway is implicated in asthma pathogenesis, with IL1RL1 nonsynonymous genetic polymorphisms associated with disease risk. We aimed to determine these variants' effect on IL1RL1 signalling induced by different IL33 isoforms thought to be elevated in the asthmatic airway. Method In a project funded by GSK plc, which has developed an IL‐33 receptor inhibitor for asthma treatment, human embryonic kidney 293 (HEK293) cells expressing secreted embryonic alkaline phosphatase (SEAP) driven by a nuclear factor kappa‐beta (NF‐κB) promoter, were transiently transfected with IL1RL1, containing one of four extracellular and Toll/interleukin 1 receptor (TIR) domain haplotypes. Cells were stimulated with seven different splice and proteolytic‐generated IL‐33 isoforms (0.001–50 ng/mL) for 24 h. Supernatant SEAP activity and interleukin‐8 (IL‐8) levels were determined. Primary human bronchial epithelial cells (HBECs) representing different genotype carriers were stimulated with IL‐33112–270 (50 ng/mL) and induced IL‐8 mRNA expression measured. Results HEK293 cells carrying both asthma extracellular and TIR domain IL1RL1 risk haplotypes presented maximal IL33‐driven signalling, with minimal signalling after IL‐33 activation in other protective haplotypes. All IL‐33 isoforms activated IL1RL1 but with differing magnitudes. Proteolytically cleaved IL3395–270 and IL33106–270 had the greatest effect and the IL33113–270, and Exon 3,4 deletion isoform exhibited the lowest. The effect of extracellular and TIR domain genetic variants on receptor signalling was replicated in primary HBECs. Maximal IL1RL1 signalling was observed in cells carrying both extracellular and TIR signalling domain risk haplotypes. Conclusions Overall, our study suggests asthma patients carrying the extracellular and TIR domain risk haplotype and have a lung microenvironment that promotes elevated levels of cleaved IL33, particularly where IL3395–270 and IL33106–270 may be more amenable to IL33/IL1RL1 targeting.

Epithelial IL-33 appropriates exosome trafficking for secretion in chronic airway disease

Activator protein transcription factors coordinate human IL-33 expression from noncanonical promoters in chronic airway disease

Epithelial overexpression of IL-33 induces eosinophilic esophagitis dependent on IL-13

Regulation of IL-33 by Oncostatin M in Mouse Lung Epithelial Cells

Lung Dysfunction in a Mouse Model of Inflammation is Dependent on T-cell-independent IL-13 Expression (54.18)

IL-33/ST2 axis deficiency exacerbates neutrophil-dominant allergic airway inflammation

Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD

Epithelial Interleukin‐1 Receptor‐Like‐1 Activation Is Contingent on Interleukin‐33 Isoforms and Asthma‐Related Receptor Variation

Cystic Fibrosis Reprograms Airway Epithelial IL-33 Release and Licenses IL-33 Dependent Inflammation

IL-33 induced inflammation exacerbated the development of chronic obstructive pulmonary disease through oxidative stress

IL-33 amplifies airways inflammation in a murine surrogate of asthma possibly through acting on dendritic cells

IL-33 Mediates Lung Inflammation by the IL-6-Type Cytokine Oncostatin M

Edwardsiella tarda induces airways inflammation and production of autoantibodies against lung tissues through regulation of the IL-33-ST2 axis

The production, function, and clinical applications of IL-33 in type 2 inflammation-related respiratory diseases

Epithelial cells expressed IL-33 to promote degranulation of mast cells through inhibition on ST2/PI3K/mTOR-mediated autophagy in allergic rhinitis

Interleukin-4 and interferon-γ orchestrate an epithelial polarization in the airways

IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk

A role for anti-IL33 strategies to limit the epithelial rhinoviral response?

Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling

Airways epithelial exposure to Streptococcus pneumoniae in the presence of the alarmin IL-33 induces a novel subset of pro-inflammatory ILC2s promoting a mixed inflammatory response

IL-36 receptor agonist and antagonist imbalance drives neutrophilic inflammation in COPD